Shorr Andrew F
Pulmonary and Critical Care Medicine and Pulmonary Clinic, Washington Hospital Center, Washington, DC 20010, USA.
Clin Infect Dis. 2007 Sep 15;45 Suppl 3:S171-6. doi: 10.1086/519473.
An understanding of the prevalence of resistant Staphylococcus aureus and the risk factors for infection with resistant isolates is essential to help clinicians choose appropriate antibiotic therapy. Selection pressure due to prior and inappropriate antibiotic use of any kind seems to be the main driving force behind the increasing rates of multidrug resistance in methicillin-resistant S. aureus (MRSA) strains. Resistance to glycopeptide antibiotics in MRSA has also emerged in recent years, along with increased use of vancomycin to treat serious infections due to MRSA. Infections due to MRSA are associated with significantly increased morbidity, mortality, length of hospital stay, and costs, compared with infections due to methicillin-susceptible S. aureus, despite adjustment for disease severity and initially appropriate antibiotic treatment. Improvements in the preparation and dissemination of antibiograms, along with adequate public reporting of MRSA trends, are needed to address the challenge of choosing appropriate initial antibiotic treatment for MRSA infections.
了解耐甲氧西林金黄色葡萄球菌的流行情况以及感染耐药菌株的危险因素,对于帮助临床医生选择合适的抗生素治疗至关重要。由于既往不恰当使用任何类型的抗生素所产生的选择压力,似乎是耐甲氧西林金黄色葡萄球菌(MRSA)菌株多重耐药率上升的主要驱动力。近年来,随着万古霉素用于治疗由MRSA引起的严重感染的使用增加,MRSA对糖肽类抗生素的耐药性也已出现。尽管对疾病严重程度进行了调整并采用了初始适当的抗生素治疗,但与甲氧西林敏感金黄色葡萄球菌引起的感染相比,MRSA引起的感染与发病率、死亡率、住院时间和成本的显著增加相关。为应对为MRSA感染选择合适的初始抗生素治疗这一挑战,需要改进抗菌谱的编制和传播,并对MRSA趋势进行充分的公开报告。